Articles (*Peer Reviewed)
In English:

* 96. Rossowski WJ, Zacharia S, Mungan Z, Ozmen V, Ertan A, Baylor LM, Jiang NY, Coy D: Reduced gastric acid inhibitory effect of pGlP(1-30)NH2 fragment with potent pancreatic amylase inhibitory activity. Regulatory Peptides, 39:9-17, 1992.

* 97. Mungan Z, Arimura A, Ertan A, Rossowski WJ, Coy DH: Pituitary adenylate cyclase activating polypeptide relaxes rat gastrointestinal smooth muscle. Scand J Gastroenterol 27(5):375-380, 1992.

* 98. Lopez J, Wright JA, Hammer, RA, Ertan A: Chronic pancreatitis is associated with a high prevalence of Giardiasis. Can J Gastroenterol,6(2):73-76, 1992.

* 99. Ertan A, Hernandez RE, Campeau RJ, Geshner JR, Litwin MS: Extracorporeal shock-wave lithotripsy and ursodiol vs ursodiol alone in the treatment of gallstones. Gastroenterology, 103:311-316,1992.

*100. Hammer RA, Ochoa A, Fernandez C, Ertan A, Arimura A: Somatostatin as a mediator of the effect of neurotensin on pentagastrin - stimulated acid secretion in rats. Peptides, 13:1175-1179, 1992.

*101. Rossowski WJ, Zacharia S, Jiang NJ, Mungan Z, Mills MR, Ertan A, Coy DH: Galanin: structure-dependent effect on pancreatic amylase secretion and jejunal strip contraction. Eur J Pharmacol, 240:259-267, 1993.

*102. Ertan A: Profiling colorectal cancer. Annual report for cancer registry, The Methodist Hospital, 5:18-24,1993.

*103. Ertan A: Medical management of pancreatitis in 1994. Houston J Gastroenterology, 3:6-10, 1994.

*104. Ertan A, Moody DR: Ulcerative jejunitis with strictures in celiac sprue. Gastroenterol International, 7:143-144, 1994

*105. Ertan A, Schneider FE: Acute pancreatitis in long-distance runners. Amer J Gastroenterol, 90:70-71, 1995.

*106. Rabassa AA, Schwartz MR, Ertan A: Alpha-1-antitrypsin deficiency and chronic pancreatitis. Dig Dis Sc, 40:1997-2001, 1995.

*107. Ertan A, Woods K: Laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography. Houston J Gastroenterology, 5-8, 1995.

*108. Ertan A: Endoscopic therapy of pancreatitis. Turk J Gastroenterol 6:317-319, 1995.

*109. Ertan A: Immunomodulator therapy of IBD. Turk J Gastroenterol 6:320-322, 1995.

*110. Ertan A, Zimmerman M, Younes M: Esophageal adenocarcinoma associated with Barrett's esophagus: long-term management with laser ablation. Amer J Gastroenterology 90:2201-2203, 1995.

*111. Ertan A, Schwartz M, Rabassa A: Alpha-1-antitrypsin deficiency and chronic pancreatitis. Dig Dis Sc, 41:550-551, 1996 (LTE,response).

*112. Mungan Z, Hammer RA, Akarca US, Komaki G, Ertan A, Arimura A: Effect of PACAP on gastric acid secretion in rats. Peptides 16:1051-1056, 1996.

*113. Ertan A: Endoscopic pancreatic stenting following pancreatic papilla dilation without pancreatic sphincterotomy. Turk J Gastroenterol, 8:402-405, 1997.

*114. Younes M, Ertan A, Lechago LV, Somoano J, Lechago J: Human erythrocyte glucose transporter (glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol Biomarkers Prev, 6:303-305, 1997

*115. Younes M, Ertan A, Lechago LV, Somoano J, Lechago J: p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci, 42:697-701, 1997.

*116. Ertan A: Endoscopic management of acute pancreatitis. Current Practice of Medicine. 2(5):98-101, 1999.

*117. Younes M, Schwartz M, Ertan A, Finnie D, Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer, 88:524-8, 2000.

*118. Younes M, Lechago J, Ertan A, and others: Relationship between dysplasia, p53 protein accumulation, DNA Ploidy, and Glut1 over expression in Barrett metaplasia. Scand J Gastroenterol. 35:131-7, 2000.

*119. Younes M, Lechago J, Ertan A, Finnie D, Younes A: Decreased expression of Fas (CD95/AP01) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol. 31:434-438, 2000.

*120 Ertan A: Long-term results after endoscopic pancreatic stenting without pancreatic papillotomy in acute recurrent pancreatitis due to pancreas divisum. Gastrointest Endosc. 52:9-14, 2000.

*121. Ertan A Younes M: Barrett's esophagus (Editorial). Dig Dis Sci, 45:1670-1673, 2000.

*122. Younes M, Lechago J, Ertan A: Photodynamic therapy and genetic abnormalities. Gastroenterology, 120: 1065-6, 2001 (LTE).

*123. Ertan A: Treatment of gallstones by extracorporeal shock wave lithotripsy. Am J Gastroenterol, 97: 831-2, 2002.

*124. Dural TA, Ertan A: Endoscopic retrieval of proximally migrated dorsal pancreatic duct stent in a patient with pancreas divisium. Med Sci, 3:65-17, 2002

*125. Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldsblum JR, Falk GW, Ertan A, Younes M: Acid supression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol, 97: 1340 - 5, 2002.

*126. Younes M, Henson DE, Ertan A, Miller CC: Incidence and survival trends of esophageal carcinoma in the United States. Racial and gender differences by histological type. Scand J Gastroenterol, 37:1359-65, 2002.

*127. Liu L, Ergun G, Ertan A, et al: Detection of oxidative DNA damage in esophageal biopsies of patients with reflux symptoms and normal pH Monitoring. Aliment Pharmacol. Ther, 18: 693-8, 2003

*128. Younes M, Ertan A, Lechago J: p53 protein anad malignant progression in Barrett's metaplasia. Am J Gastroenterol, 95: 1200-1, 2003 (LTE).

*129 Gonlusen, G., Akgun H, Ertan A, et al:  Renal failure and nephrocalcinosis associated with oral phosphate bowel cleansing--Clinicial patterns and renal biopsy findings.  Arch Pathol Lab Med, 129:  71-76, 2005.

*130. Ertan A: Irritable bowel syndrome in women. Journal Watch Women' Health [the publisher of NEJM]. 10:68-9, 2005.

*131. Peter MB, Obermeyer RJ, Ojeda HF …, Ertan A, et al: Laparascopic management of colon lipomas. JSLS, 9: 342-4, 2005.

*132. Chen X, Lechago J, Ertan A, et al: Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia. Cancer Epidemiology, Biomarkers and Prevention, 13: 30-3, 2005.

*133. Sanborn WJ, Colombel JF, Enns R, et al: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med, 353: 1912-25, 2005 (Ertan A as a participating investigator).

*134. Younes M, Ertan A, Ergun G, et al: Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia. Arch Path Lab Med, 131: 571-5, 2007.

*135. Targan SR, Feagan BG, Fedorak RN, et al: Natalizumab for the treatment of active Crohn’s disease: Results of the ENCORE trial. Gastroenterology, 132: 1672-83, 2007 (Ertan A ,as a participating investigator).

*136. Younes M, Ertan A, Ergun G, et al: Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia. Arch Pathol Lab Med. 131; 571-5, 2007.

*137. Ertan A: Kemal Akdamar. Guncel Gastroenteroloji. 11:18-21, 2007.

*138. Ergun GA, Ertan A: Non-surgical management of Barrett’s dysplasia. Houston Medical Journal. 11 & 21-4, 2008.

*139. Younes M, Lauwers G, Ertan A, et al: The significance of indefinite for dysplasia grading in Barrett’s metaplasia. Modern Pathology, 132; 36-40, 2009.

*140. Ertan A, Botoman VA: International gastroenterology and American College of Gastroenterology. Am J Gastroenterol, 2010 (in press).

*141. Blackmon S, Zaheer I, Barrosso A, Ertan A: Photodynamic therapy versus radiofrequency ablation therapy in Barrett’s esophagus with dysplasia. Ann Surg, 2010 (submitted).

*142. Lichtenstein GR, Thomsen O, Schreiber S, et al:  Continous therapy with Certolizumab Pegol maintains remission of patients with Crohn's disease for up to 18 months.  Clin Gasterenterol Hepatol, 8; 600-9, 2010 (Ertan A as a participating investigator).

*143. Younes M, Lauwers G, Ertan A, et al:   The significance of indefinite for dysplasia grading in Barrett's metaplasia.   Arch Pathol Lab Med, 135, 430-33, 2011.

*144. Shaheen NJ, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, et al:  Prior fundoplication does not improve subsequent safety or efficacy outcomes of radiofrequency ablation (RFA): Results from the US RFA Registry.  AJS, 2012 (Accepted).

*145. Blackmon S, Zaheer I, Barroso A, Ertan A:  Photodynamic therapy versus radiofrequency ablation therapy in Barrett’s esophagus with dysplasia.  WJG, 2012 (submitted).

*146. Villa N, El-Serag H, Younes M, Ertan A: Esophageal eosinophilia after radiofrequency ablation for Barrett’s esophagus. Esophagus, 2012 (submitted).

Please download Dr. Ertan's CV for up-to-date publications.